• RMR Science Technologies Inc. (RMS.P) receives conditional approval for its proposed qualifying transaction with Turnium Technology Group, Inc. (TTGI)
  • RMR is a capital pool company and TTGI is a global software company
  • The TSXV also approved the filing of RMR’s filing statement
  • RMR also announces that it has refiled its interim financial statements
  • RMR Science Technologies Inc. (RMS.P) is unchanged trading at $0.10 per share as of 12:51 p.m. EST

RMR Science Technologies (RMS.P) has received conditional approval from the TSXV for its proposed qualifying transaction with Turnium Technology Group, Inc. (TTGI).

RMR is a capital pool company and TTGI is a global software company.

The conditional approval is valid until May 15. The TSXV also approved the filing of RMR’s filing statement dated February 14.

Subject to the satisfaction of all conditions of the amalgamation agreement entered between RMR, its subsidiary and TTGI, the qualifying transaction is expected to close by March 25. RMR expects the Class A common shares of the combined entity to begin trading on the TSXV under the symbol TTGI by March 31.

RMR also announces that it has refiled its interim financial statements from its previous fiscal quarter with an amended corresponding management discussion and analysis.

RMR has amended and restated its unaudited consolidated financial statements reflecting the following changes:

  • To restate the balance of reserves as of December 31, 2021
  •  To restate share-based compensation
  • To restate the deficit
  • To restate the weighted average common shares outstanding, both basic and diluted

RMR Science Technologies Inc. (RMS.P) is unchanged trading at $0.10 per share as of 12:51 p.m. EST.

More From The Market Online

Liberty Defense expands its international customer base

Liberty Defense Holdings (TSXV:SCAN), a provider of artificial intelligence technologies, expands its international customer base.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.